Citations (2)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Shonali Midha, Monique A. Hartley-Brown, Clifton C. Mo, Shahrier Hossain, Omar Nadeem, Elizabeth K. O’Donnell, Giada Bianchi, Adam S. Sperling, Jacob P. Laubach & Paul G. Richardson. (2023) A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma. Expert Opinion on Drug Safety 22:11, pages 1049-1071.
Read now
Read now
Articles from other publishers (1)
Faouzi Djebbari, Alexandros Rampotas, Grant Vallance, Fotios Panitsas, Nanda Basker, Gina Sangha, Beena Salhan, Farheen Karim, Firas Al‐Kaisi, Amy Gudger, Loretta Ngu, Matt Poynton, Ho Pui Jeff Lam, Lowri Morgan, Laura Yang, Jennifer Young, Mairi Walker, Ismini Tsagkaraki, Laura Anderson, Saleena Rani Chauhan, Rebecca Maddams, Richard Soutar, Margarita Triantafillou, Steve Prideaux, Abubaker Obeidalla, Toby A. Eyre, Ceri Bygrave, Jaimal Kothari, Supratik Basu & Karthik Ramasamy. (2023)
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a
UK
‐wide real‐world cohort of relapsed myeloma patients
. British Journal of Haematology 201:1, pages 162-167.
Crossref
Crossref